Home/Pipeline/AAV-GAD

AAV-GAD

Parkinson's Disease

Preclinical/Phase 1Development ongoing

Key Facts

Indication

Parkinson's Disease

Phase

Preclinical/Phase 1

Status

Development ongoing

Company

MeiraGTx

About MeiraGTx

MeiraGTx is focused on advancing a pipeline of gene therapies for serious conditions with high unmet medical need, primarily in ophthalmology and neurology. The company's core strength lies in its integrated platform encompassing vector design, promoter engineering, and manufacturing capabilities. Key strategic partnerships, including a significant collaboration with Janssen Pharmaceuticals, provide validation and resources for its lead programs. The company is navigating the complex clinical and regulatory pathway typical of gene therapy developers.

View full company profile

Therapeutic Areas

Ophthalmology Neurology Rare Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
ABBV-951	AbbVie	Phase 3	Active
UCB0107	UCB	Phase 1	Active
Stalevo	Orion Corporation	Approved	Commercial
Comtan/Comtess	Orion Corporation	Approved	Commercial
CHRONOS-PD Platform	Grifols	Research	Active
GT-001 (Gene Therapy)	Sumitomo Pharma	Phase 1/2	Active
CREXONT (Carbidopa/Levodopa)	Amneal Pharmaceuticals	Approved	Launched
BIIB122/DNL151	Denali Therapeutics	Phase 3	Active (LIGHTHOUSE study)
ABBV-0805	BioArctic AB	Phase 1	Completed (Partnered with AbbVie)
BAN1202	BioArctic AB	Preclinical	Proprietary program
ARV-102	Arvinas	Phase 1	Active - >50% LRRK2 degradation in CSF reported
Not Specified	Minerva Neurosciences	Clinical Stage	Active Development